Nicola Falzon

Nicola Falzon currently serves as Corporate Controller at Denali Therapeutics, having been with the company since April 2016 and previously holding roles as Director of Corporate Finance and Group Lead Finance. Prior to Denali Therapeutics, Nicola Falzon was with KPMG from September 2003 to March 2016, rising to the position of Audit Senior Manager and specializing in the life sciences sector, where contributions included audits for biotechnology and pharmaceutical companies. Earlier experience includes roles at Aventis and AstraZeneca Pharmaceuticals, focusing on clinical inspection and research assistance, respectively. Nicola Falzon holds a degree in Molecular Biology with Industrial Experience from The University of Manchester and is a qualified Chartered Accountant through ICAEW.